Global healthcare company, Abbott, announced that its continuous glucose monitoring system Lingo can now be purchased in the U.S. without a prescription.
Lingo contains a biosensor and mobile app that is based on Abbott's FreeStyle Libre continuous glucose monitoring technology.
The system is a bio wearable product intended for people older than 18 years who are not taking insulin.
It tracks...
India and US-based metabolic fitness platform, Ultrahuman has announced it has raised €14.8 million ($17.5m), to build on its goal to help people suffering from metabolic health disorders.
The Series B funding came from a range of London-based investors including, Alpha Wave Incubation (AWI), which is backed by DisruptAD and managed by Falcon Edge, Steadview Capital, Nexus Venture Partners, Blume...
This morning Abbott revealed that its much anticipated integrated continuous glucose monitoring system the FreeStyle Libre 2 is now FDA cleared for adults and kids over the age of 4 with diabetes.
The latest product is able to continuously transmit glucose data every minute, and users can set the system to send alarms when their glucose is too high or too low. Previously users had to scan the...
This morning med tech giant Abbott announced a new deal with chronic care management company Omada Health that will integrate Abbott’s FreeStyle Libre continuous glucose monitor (CGM) with Omada's health coaching platform.
Going forward, eligible users with Type 2 diabetes will have the option to integrate data from their FreeStyle Libre, including glucose reading, trends and patterns, with...
A diabetes startup that uses artificial intelligence, Bigfoot Biomedical, has just announced that it scored a total of $55 million in Series B equity financing with new investments from Abbott and other existing funders.
This funding is the culmination of earlier round funding that the company has been raising since late last year, including $37 million that it raised in December and an...
Abbott Diabetes Care's Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to the US where Abbott is based, the approval also represents a first for continuous glucose monitoring, as it doesn't require the user to use a fingerstick, even for calibration.
"From an emotional...
Abbott Diabetes Care shared some real-world evidence this morning at the International Conference on Advanced Technologies & Treatments for Diabetes, bolstering clinical trial data about the effectiveness of the company's Freestyle Libre device line.
"We’re certainly committed to sharing as much information as is possible with our users and our health providers in order to be able to make...
Abbott has received FDA Clearance for its FreeStyle Libre Pro system, a key milestone in bringing the company's unique take on the continuous glucose monitor to the United States. In Europe, where the system has had CE Mark clearance since September 2014, there is both a prescription and over-the-counter version available and the latter is smartphone compatible.
"FreeStyle Libre Pro transforms...
